

# Heart Valve Disease

Treatment approaches covered

Pharmacological, transcatheter/surgical intervention, and communicate steps for management, self-care and follow-up care

Population covered: Adults ( $\geq 18$  years old) with heart valve disease

In partnership with



## Details

1 Includes Early Mortality, Late Mortality, Valve-related Mortality and All-cause Mortality

2 Defined by the EQ-5D-5L questionnaire

3 Defined by the Impact on Mental Health & Daily Activities questionnaire (IDCV)

4 Includes Aortic/Mitral/Tricuspid valve stenosis and Aortic/Mitral/Tricuspid valve regurgitation

5 Includes Angina Pectoris and NYHA functional class

6 Includes Stroke (ischemic/hemorrhagic) and Thromboembolic event (non-cerebral)

7 Includes Conversion to open-heart surgery, Reoperation for bleeding, Periprocedural myocardial infarction, New permanent pacemaker, Major/minor vascular complications, Low-cardiac output syndrome, Hospital stay and ICU Stay

8 Includes Paravalvular insufficiency and Device migration (only applicable to percutaneous devices)

9 Refers to Structural and Non-Structural valve dysfunction

For a complete overview of the Set, including definitions for each measure, time points for collection, and associated risk factors, visit [ichom.org/medical-conditions/Heartvalvedisease](https://ichom.org/medical-conditions/Heartvalvedisease)

# Contributors


For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit [ichom.org/how-we-work/](http://ichom.org/how-we-work/)

## The Sponsors



## In Collaboration With

## The Working Group



### Project Team

#### Chair

Hanneke Takkenberg | Erasmus University Medical Campus, Rotterdam

#### Chair

Emmanuel Lansac | Hôpital Pitié Salpêtrière

#### Research Fellow

Kevin Veen | Erasmus University Medical Campus, Rotterdam

#### Project Manager

Andria Joseph | ICHOM

#### Project Manager

Paula Blancarte Jaber | ICHOM

#### Research Associate

Frieda Sossi | ICHOM

#### Director of Outcomes Research

Zofia Das-Gupta | ICHOM

### Australia

Aubrey Almeida | Monash Medical Centre; Australian & New Zealand Society of Cardiac & Thoracic Surgeons  
Philip Holmes\*

### Austria

Andreas Zuckermann | Medical University of Vienna

### Belgium

Bart Meuris | K.U. Leuven, Heart Valve Society (HVS)

### Canada

John Stott\* | Heart Valve Voice Canada

### Germany

Evaldas Girauskas | University Heart Center Hamburg;  
Heart Valve Society

### Italy

Silvana Medica\*

### The Netherlands

Jolanda Kluin | Academic Medical Centre and University of Amsterdam; HVS;  
European Association for Cardio-Thoracic Surgery (EACTS)

### Norway

Gry Dahle | Rikshospitalet; International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS)

### Spain

Rafael Sádaba | Hospital Universitario de Navarra; European Association for Cardio-Thoracic Surgery

### South Africa

Ruchika Meel | Chris Hani Baragwanath Hospital; University of the Witwatersrand; South African Heart Association

### United Kingdom

Suleman Aktaa | Leeds Institute of Cardiovascular and Metabolic Medicine; European Society of Cardiology  
Wil Woan | Heart Valve Voice UK  
Daniel Colgan\*

### United States

Elena Aikawa | Harvard University; ISACB  
Faisal G. Bakaeen | Cleveland Clinic; STS

Frederick Schoen | Brigham and Women's Hospital; Harvard Medical School; ISACB

Hani Jneid | Baylor College of Medicine; AHA

Husam Balkhy | University of Chicago; ISMICS

Molly Szerlip | The Heart Hospital Baylor Plano; ACC

Ourania Preventza | Baylor College of Medicine; AATS

Pinak Shah | Brigham and Women's Hospital; ACC

Vera H. Rigolin | Northwestern University; AHA

Wilson Y. Szeto | University of Pennsylvania

\*Patient Representative